Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
-
Publication number: 20140154255Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.Type: ApplicationFiled: November 26, 2013Publication date: June 5, 2014Applicant: AbbVie Biotherapeutics Inc.Inventor: Yoshiko AKAMATSU
-
Patent number: 8741295Abstract: The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.Type: GrantFiled: February 9, 2010Date of Patent: June 3, 2014Assignees: Universite de la Mediterranee, Inserm (Institut National de la Sante et de la Recherche Medicale)Inventor: Daniel Olive
-
Publication number: 20140148388Abstract: The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric FGF polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.Type: ApplicationFiled: August 7, 2013Publication date: May 29, 2014Applicant: GENENTECH, INC.Inventor: Junichiro SONODA
-
Patent number: 8734797Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: October 18, 2011Date of Patent: May 27, 2014Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8734801Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: October 18, 2011Date of Patent: May 27, 2014Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8728761Abstract: Transformed microalgae capable of expressing glycosylated polypeptides and methods for producing said transformed microalgae and producing glycosylated polypeptides.Type: GrantFiled: February 12, 2009Date of Patent: May 20, 2014Assignees: Institut Francais de Recherche pour l'Exploitation de la Mer (IFREMER), Centre National de la Recherche Scientifique—CNRS, Universite de RouenInventors: Jean-Paul Cadoret, Aude Carlier, Patrice Lerouge, Muriel Bardor, Carole Burel, Florian Maury
-
Patent number: 8728469Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: GrantFiled: April 11, 2013Date of Patent: May 20, 2014Assignee: ZymoGenetics, Inc.Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
-
Patent number: 8722033Abstract: Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.Type: GrantFiled: October 26, 2010Date of Patent: May 13, 2014Assignee: Amgen Inc.Inventors: Jennifer E. Towne, Janet D. Cheng, Jason C. O'Neill, Yu Zhang, Yu Sun, Heather Cerne, Derek E. Piper, Randal R. Ketchem
-
Patent number: 8722860Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.Type: GrantFiled: April 16, 2010Date of Patent: May 13, 2014Assignee: AbbVie Biotherapeutics Inc.Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
-
Patent number: 8715669Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: GrantFiled: December 28, 2011Date of Patent: May 6, 2014Assignee: Novimmune SAInventors: Krzysztof Masternak, Olivier Leger
-
Patent number: 8716449Abstract: The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.Type: GrantFiled: July 19, 2005Date of Patent: May 6, 2014Assignee: Hoffman-LaRoche, Inc.Inventors: Maurice Kent Gately, David Howard Presky
-
Patent number: 8715663Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: April 28, 2011Date of Patent: May 6, 2014Assignee: Amgen Inc.Inventors: Christopher J. Paszty, Hsieng Sen Lu
-
Patent number: 8715941Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.Type: GrantFiled: November 14, 2008Date of Patent: May 6, 2014Assignee: Arca Biopharma, Inc.Inventors: Arie Abo, Minke Binners
-
Patent number: 8715664Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: GrantFiled: May 16, 2006Date of Patent: May 6, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg
-
Publication number: 20140120115Abstract: The present disclosure relates to antigen-binding moieties that specifically bind to MIF and D-DT and compositions and methods of use thereof.Type: ApplicationFiled: July 13, 2012Publication date: May 1, 2014Applicant: MorphoSys AGInventors: Swen Zierow, Juergen Klattig
-
Patent number: 8703131Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.Type: GrantFiled: May 17, 2006Date of Patent: April 22, 2014Assignee: Ablynx N.V.Inventor: Els Anna Alice Beirnaert
-
Patent number: 8691953Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: December 20, 2011Date of Patent: April 8, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
-
Patent number: 8679489Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.Type: GrantFiled: February 8, 2013Date of Patent: March 25, 2014Assignee: XBiotech, Inc.Inventor: John Simard
-
Patent number: 8679494Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: GrantFiled: April 22, 2009Date of Patent: March 25, 2014Assignee: UCB Pharma S.A.Inventors: Thomas Allen Ceska, Alistair James Henry
-
Patent number: 8680245Abstract: The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF.Type: GrantFiled: May 26, 2010Date of Patent: March 25, 2014Assignee: Glaxo Group LimitedInventors: Claire Ashman, Jonathan Henry Ellis, Paul Andrew Hamblin, Alan Peter Lewis, Martin Anibal Orecchia
-
Patent number: 8679502Abstract: Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.Type: GrantFiled: November 12, 2008Date of Patent: March 25, 2014Assignees: Evec Inc., Boehringer Ingelheim International GmbHInventors: Kenzo Takada, Kantou Nakajima, Barbara Kistler, John Park
-
Patent number: 8673299Abstract: The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.Type: GrantFiled: August 11, 2011Date of Patent: March 18, 2014Assignee: NovImmune S.A.Inventors: Nicolas Fischer, Marie Kosco-Vilbois, Francois Mach
-
Patent number: 8668909Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: GrantFiled: April 26, 2010Date of Patent: March 11, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Patent number: 8663636Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.Type: GrantFiled: April 13, 2012Date of Patent: March 4, 2014Assignee: MedImmune, LLCInventors: Ian Foltz, David Jenkins, Vahe Bedian
-
Patent number: 8658169Abstract: The present invention relates to IL-25 antibody VH domains and target binding members (e.g., antibodies) that comprise such antibody VH domains and bind IL-25. The invention also relates to compositions comprising target binding members {e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).Type: GrantFiled: September 30, 2009Date of Patent: February 25, 2014Assignee: Medical Research CouncilInventors: David John Matthews, Jillian Barlow, Andrew Neil James McKenzie
-
Patent number: 8648175Abstract: The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with PVP.Type: GrantFiled: November 8, 2002Date of Patent: February 11, 2014Assignee: Lek Pharmaceuticals d.d.Inventors: Andreja Vukmirovic, Tanja Rozman Peterka, Jelka Svetek, Alenka Paris
-
Patent number: 8642741Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.Type: GrantFiled: November 8, 2011Date of Patent: February 4, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Brendan J. Classon, Dimitris Skokos
-
Patent number: 8642034Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.Type: GrantFiled: October 3, 2007Date of Patent: February 4, 2014Assignee: Genzyme CorporationInventors: James B. Streisand, Jesse D. Roberts, Jr.
-
Patent number: 8642740Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.Type: GrantFiled: July 6, 2012Date of Patent: February 4, 2014Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
-
Patent number: 8637019Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.Type: GrantFiled: November 2, 2010Date of Patent: January 28, 2014Assignee: Merck Sharp & Dohme Corp.Inventor: Leonard G. Presta
-
Patent number: 8637030Abstract: The present invention provides a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a S-100 protein, b) an activated-potentiated form of an antibody to histamine, and c) an activated-potentiated form of an antibody to TNF-alpha. Various embodiments and variants are provided. The present invention further provides a method of treating a disease or condition of functional etiology of the gastrointestinal tract, said method comprising administering to a patient in need thereof a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a histamine, b) an activated-potentiated form of an antibody to S-100 protein and c) an activated-potentiated form of an antibody to TNF-alpha. Various embodiments and variants are provided.Type: GrantFiled: July 15, 2011Date of Patent: January 28, 2014Inventor: Oleg Iliich Epshtein
-
Patent number: 8637034Abstract: The preset invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections.Type: GrantFiled: July 15, 2011Date of Patent: January 28, 2014Inventor: Oleg Iliich Epshtein
-
Patent number: 8632778Abstract: The present invention provides stabilized preparations containing an antibody in a glycine buffer and/or a histidine buffer and also provides processes for preparing a protein-containing stabilized preparation, comprising adjusting the pH with a basic amino acid or a basic amino acid derivative or a salt thereof.Type: GrantFiled: August 13, 2001Date of Patent: January 21, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masaya Kakuta, Tadao Yamazaki, Akira Hayasaka, Yoshiki Hayashi, Tsutomu Arakawa
-
Patent number: 8632774Abstract: A binding domain polypeptide and fusion proteins thereof that recognize an IL6/IL6 receptor complex, as well as compositions and methods of use thereof.Type: GrantFiled: July 2, 2009Date of Patent: January 21, 2014Assignee: Emergent Product Development Seattle, LLCInventors: Lynda Misher, Alan Keith Lofquist, Peter Robert Baum, Peter Armstrong Thompson
-
Publication number: 20140017256Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.Type: ApplicationFiled: February 7, 2013Publication date: January 16, 2014Applicant: ABBVIE INC.Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
-
Patent number: 8623367Abstract: The present invention relates to novel pharmaceutical formulations, in particular novel pharmaceutical formulations in which the active ingredient comprises human antibodies to human interleukin I beta (IL-1?), in particular ACZ885 antibody, pharmaceutical formulations which are stable and aggregate-free upon storage and delivery.Type: GrantFiled: August 15, 2012Date of Patent: January 7, 2014Assignee: Novartis AGInventors: Joachim Momm, Hans-Joachim Wallny
-
Patent number: 8624002Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.Type: GrantFiled: July 8, 2009Date of Patent: January 7, 2014Assignee: AbbVie, Inc.Inventors: Jjijie Gu, Charles W. Hutchins, Rong-rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Anwar Murtaza, Edit Tarcsa, William B. Stine, Chung-ming Hsieh
-
Patent number: 8617847Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: GrantFiled: October 1, 2012Date of Patent: December 31, 2013Assignee: UCB Pharma S.A.Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
-
Patent number: 8609099Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: July 8, 2010Date of Patent: December 17, 2013Assignee: Zymogenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica Huber
-
Patent number: 8609817Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.Type: GrantFiled: July 29, 2009Date of Patent: December 17, 2013Assignee: Eli Lilly and CompanyInventors: Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi
-
Patent number: 8609101Abstract: The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species.Type: GrantFiled: April 23, 2010Date of Patent: December 17, 2013Assignee: Theraclone Sciences, Inc.Inventors: Po-Ying Chan-Hui, Steven Frey, Andres G. Grandea, III, Thomas C. Cox
-
Patent number: 8609093Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: GrantFiled: March 1, 2012Date of Patent: December 17, 2013Assignee: Novimmune S. A.Inventors: Krzysztof Masternak, Francois Rousseau
-
Patent number: 8603778Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: GrantFiled: July 12, 2012Date of Patent: December 10, 2013Assignee: Janssen Biotech, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Patent number: 8604174Abstract: The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided.Type: GrantFiled: April 18, 2006Date of Patent: December 10, 2013Assignee: Amgen Inc.Inventors: John Babcook, Palaniswami Rathanaswami, Orit Foord, Jaspal S. Kang
-
Patent number: 8597648Abstract: The present invention provides a full human anti-TNF-? monoclonal antibody, the preparation method and use thereof. The antibody in the present invention has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The antibody in the present invention can be used to prepare medicines for the treatment of autoimmune disorders.Type: GrantFiled: April 16, 2010Date of Patent: December 3, 2013Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.Inventors: Huaizu Guo, Chuan Li, Xin Tong
-
Patent number: 8597659Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.Type: GrantFiled: August 29, 2011Date of Patent: December 3, 2013Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 8597647Abstract: The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.Type: GrantFiled: May 22, 2012Date of Patent: December 3, 2013Assignee: National Cheng Kung UniversityInventors: Ming-Shi Chang, Naoya Tsurushita, Shankar Kumar
-
Patent number: 8597646Abstract: The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.Type: GrantFiled: October 25, 2006Date of Patent: December 3, 2013Assignee: The Johns Hopkins UniversityInventors: Harry C. Dietz, Daniel P. Judge, Enid R. Neptune, Ronald Cohn, Jennifer Habashi
-
Patent number: 8592563Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, against agonist pro-angiogenic, pro-permeability, vasodilatory isoforms of VEGF. Disclosed antibodies and antibody fragments are characterized by being capable of binding to and neutralizing pro-angiogenic forms of VEGF while not effecting isoforms of VEGF which are anti angiogenic. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.Type: GrantFiled: October 26, 2008Date of Patent: November 26, 2013Assignees: Philogene, Inc., University of BristolInventors: David O. Bates, Steven J. Harper, Miriam Y. Mengelus, Menachem Ze'evi
-
Patent number: 8591898Abstract: The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome.Type: GrantFiled: December 17, 2008Date of Patent: November 26, 2013Assignee: Pfizer LimitedInventors: Ian William Mills, Stephen Charles Phillips, Arnon Rosenthal, David Peter Scholfield, David Louis Shelton